13 completed. 13 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 13 | Completed 13 |
| Phase 2 | 2 | Completed 2 |
Follow Thrombophilia: new trials by email Literature Review of Thrombophilia trials Research Report on Thrombophilia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura Caplacizumab, Corticosteroids, anti-CD20 antibody - Thrombotic Thrombocytopenic Purpura | Phase 3 | Completed | Sanofi | 51 | 2022-11-21 | 2025-12-30 |
| A Trial of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP) Caplacizumab (ALX-0081), Plasma exchange (PE), Corticosteroid treatment (Methylprednisolone or prednisolone) - Thrombotic Thrombocytopenic Purpura | Phase 2 / Phase 3 | Completed | Sanofi | 21 | 2019-10-21 | 2025-09-22 |
| A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP) TAK-755, Standard of care - Thrombotic Thrombocytopenic Purpura (TTP) | Phase 3 | Completed | Baxalta now part of Shire | 52 | 2017-10-13 | 2026-02-09 |
| Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES) Caplacizumab, Standard of Care - Acquired Thrombotic Thrombocytopenic Purpura | Phase 3 | Completed | Sanofi | 104 | 2016-10-06 | 2022-03-28 |
| Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura Caplacizumab, Placebo - Acquired Thrombotic Thrombocytopenic Purpura | Phase 3 | Completed | Ablynx, a Sanofi company | 145 | 2015-11-01 | 2023-04-05 |
| A Clinical Study of KW-3357 in Patients With DIC KW-3357 - Disseminated Intravascular Coagulation (DIC) | Phase 3 | Completed | Kyowa Kirin Co., Ltd. | 15 | 2011-12-01 | 2017-03-24 |
| An Open-label Study of KW-3357 KW-3357, Plasma-derived antithrombin - Disseminated Intravascular Coagulation (DIC) | Phase 3 | Completed | Kyowa Kirin Co., Ltd. | 221 | 2011-06-01 | 2017-03-24 |
| Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in Thrombotic Thrombocytopenic Purpura (TTP) Cyclosporine, Prednisone - Thrombotic Thrombocytopenic Purpura | Phase 3 | Completed | Ohio State University | 26 | 2007-11-01 | 2023-05-03 |
| Recombinant Human Antithrombin (rhAT) in Patients With Hereditary Antithrombin Deficiency Undergoing Surgery or Delivery Recombinant human antithrombin (rhAT) - Antithrombin III Deficiency | Phase 3 | Completed | rEVO Biologics | 18 | 2005-04-01 | 2012-08-17 |
| Efficacy and Safety Study of Protein C Concentrate in Subjects With Severe Congenital Protein C Deficiency Protein C Concentrate (Human) Vapor Heated - Protein C Deficiency | Phase 2 / Phase 3 | Completed | Baxalta now part of Shire | 18 | 2003-08-22 | 2021-05-05 |
| Assess Incidence of Deep Vein Thrombosis(DVT)Following Administration of Recombinant Human Antithrombin (rhAT) to Hereditary Antithrombin(AT) Deficient Patients in High Risk Situations. Recombinant Human Antithrombin (rhAT) - Antithrombin Deficiency, Congenital | Phase 3 | Completed | rEVO Biologics | 14 | 2002-12-01 | 2012-10-16 |
| Low Molecular Weight Heparin and/or Aspirin in Prevention of Habitual Abortion Aspirin, Klexane, Klexane and ASA - Habitual Abortion | Phase 3 | Completed | University of Helsinki | 220 | 2002-01-01 | 2009-08-14 |
| TIPPS: Thrombophilia in Pregnancy Prophylaxis Study dalteparin sodium - Pregnancy, Thrombophilia | Phase 3 | Completed | Ottawa Hospital Research Institute | 292 | 2000-07-01 | 2014-05-19 |
Purpura, Thrombotic Thrombocytopenic (6) · Antithrombin III Deficiency (2) · Disseminated Intravascular Coagulation (2) · Abortion, Habitual (1) · Abortion, Spontaneous (1) · Pre-Eclampsia (1) · Pregnancy Complications (1) · Premature Birth (1) · Protein C Deficiency (1) · Recurrence (1) · Stillbirth (1)
Hematologic Diseases (13) · Hemic and Lymphatic Diseases (13) · Blood Coagulation Disorders (11) · Pathologic Processes (7) · Pathological Conditions, Signs and Symptoms (7) · Blood Platelet Disorders (6) · Cytopenia (6) · Hemorrhage (6) · Purpura (6) · Purpura, Thrombocytopenic (6) · Signs and Symptoms (6) · Skin Manifestations (6) · Thrombocytopenia (6) · Thrombotic Microangiopathies (6)
caplacizumab (4) · Prednisolone (2) · Prednisone (2) · Rituximab (2) · Standard of Care (2) · ADAMTS13 protein, human (1) · Adrenal Cortex Hormones (1) · Aspirin (1) · Biosimilar Pharmaceuticals (1) · Cyclosporine (1) · Dalteparin (1) · Methylprednisolone (1) · Plasma Exchange (1) · Protein C (1)
Sanofi (3) · Baxalta now part of Shire (2) · Kyowa Kirin Co., Ltd. (2) · rEVO Biologics (2) · Ablynx, a Sanofi company (1) · Ohio State University (1) · Ottawa Hospital Research Institute (1) · University of Helsinki (1)
United States (9) · France (6) · Italy (6) · United Kingdom (6) · Canada (5) · Germany (5) · Japan (5) · Austria (4) · Spain (4) · Belgium (3) · Czechia (3) · Australia (2) · Hungary (2) · Israel (2) · Netherlands (2)
Cambell Tait, MD (1) · Janvier Visser, MD (1) · Katja Lampinen, MD (1) · Kitty Bloemenkamp, MD (1) · Laure Morin-Papunen, MD (1) · Marc A Rodger, MD (1) · Robert C Tait, MD (1) · Spero R Cataland, MD (1) · Veli-Matti Ulander, MD (1) · William Hague, MD (1)
PMID 24335249, PMID 22449204, PMID 25066248, PMID 29296854, PMID 30473794, PMID 30625070, PMID 31691462, PMID 32358837, PMID 33779986, PMID 33881463, PMID 36138517, PMID 36427162, PMID 38692292, PMID 39095866, PMID 41348038
2015 (1), 2016 (1), 2017 (1)